Professor Ruth Ganss, Harry Perkins Institute of Medical Research/University of Western Australia
Intratumoral inflammation fosters angiogenesis and creates an immunosuppressive milieu. The self-amplifying loop of pro-angiogenic inflammation represents a serious obstacle for adaptive anti-cancer immune responses. We have previously demonstrated that restoration of tumour vessel function, so-called normalization, in the right inflammatory context “opens” tumours for therapy. We are developing new approaches which exploit the dynamic nature of tumour stroma to remodel rather than destroy vessels for longer lasting anti-tumour effects in particular in combination with chemo- and immunotherapies. Our findings highlight the plasticity and dynamic nature of tumour stroma and provide specific approaches to reverse angiogenesis.
Professor Ruth Ganss is Group Leader and Scientific Head of the Cancer Division at the Harry Perkins Institute of Medical Research in Perth. Her team studies vascular remodelling in the context of tumour growth and cardiovascular pathologies. During the last decades, her research at the University of California, San Francisco, the German Cancer Research Center in Heidelberg, and now at the Harry Perkins Institute has focused on blood vessels as the interfase between immunology, cancer and cardiovascular disease. She pioneered the concept of angiogenic vessel “normalization” in combination with immunotherapy. Her studies aim to provide novel mechanistic insights and develop new targets for therapeutic intervention.